Mgr. Lenka Košťálová
Technician, Marek Mráz Research Group
office: bldg. E35/281
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 7500 |
---|---|
e‑mail: |
Total number of publications: 34
2024
-
Co-culture with CD40L, IL4 and IL21 expressing stromal cells induces robust CLL cell proliferation in vitro and in PDX co-transplantations
Year: 2024, type: Conference abstract
-
FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia
The Journal of Clinical Investigation, year: 2024, DOI
-
MOLECULAR MECHANISM OF NON-GENETIC ADAPTATION TO BTK INHIBITOR THERAPY IN CLL
Year: 2024, type: Conference abstract
-
STROMAL CELLS ENGINEERED TO EXPRESS T CELL FACTORS INDUCE ROBUST CLL CELL PROLIFERATION IN VITRO AND IN PDX COTRANSPLANTATIONS ALLOWING THE IDENTIFICATION OF ANTI-PROLIFERATIVE DRUGS
Year: 2024, type: Conference abstract
-
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug
Leukemia, year: 2024, volume: 38, edition: 8, DOI
2023
-
FOX01-rictor AXIS induces AKT phosporylation during CLL cell adaptation to BCR inhibitors: Implications for combinatorial therapy.
Year: 2023, type: Conference abstract
-
FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy.
Year: 2023, type: Conference abstract
-
Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
Year: 2023, type: Conference abstract
-
Nekódující RNA v biologii maligních B lymfocytů.
Year: 2023, type: Conference abstract
-
Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL.
Year: 2023, type: Conference abstract